Purpose The aim of this proof-of-concept study was to characterize the pharmacokinetics and pharmacodynamics of intranasal dexmedetomidine compared with its intravenous administration in a small number of healthy volunteers. Methods Single doses of 84 μg of dexmedetomidine were given once intravenously and once intranasally to seven healthy men. Plasma dexmedetomidine concentrations were measured for 10 h, and pharmacokinetic variables were calculated with standard noncompartmental methods. Heart rate, blood pressure, concentrations of adrenaline and noradrenaline in plasma, and central nervous system drug effects (with the Maddox wing, Bispectral Index, and three visual analog scales) were monitored to assess the pharmacological effects of dexmedetomidine. Results Six individuals were included in the analyses. Following intranasal administration, peak plasma concentrations of dexmedetomidine were reached in 38 (15-60) min and its absolute bioavailability was 65% (35-93%) (medians and ranges). Pharmacological effects were similar with both routes of administration, but their onset was more rapid after intravenous administration. Conclusions Dexmedetomidine is rather rapidly and efficiently absorbed after intranasal administration. Compared with intravenous administration, intranasal administration may be a feasible alternative in patients requiring light sedation.
Introduction
Dexmedetomidine is a highly selective and potent alpha-2-adrenoceptor agonist indicated for perioperative and intensive care sedation. As well as offering sedation and anxiolysis, dexmedetomidine has analgesic qualities and reduces stress responses to surgical and intensive care procedures [1] . It has been shown that intranasally administered dexmedetomidine is efficacious and well tolerated in healthy volunteers [2] , which may be a useful alternative for oral midazolam as premedication in children [3] . The onset of sedation has been reported to occur at 45 min in healthy volunteers [2] and at 25 min in children [4] . However, information on the pharmacokinetics and bioavailability of dexmedetomidine after intranasal administration is lacking. The aim of this proof-of-concept study was to compare the bioavailability and pharmacokinetics of intranasally and intravenously administered dexmedetomidine in healthy volunteers and to report the effects on plasma catecholamine levels, systemic blood pressure, heart rate, and sedation.
Material and methods
The study (EudraCT 2008-008324-33, ClinicalTrials.gov identifier NCT00837187) was conducted according to the 
Study participants
After receiving approval from the Ethics Committee of the Hospital District of Southwest Finland and the Finnish Medicines Agency, written informed consent was obtained from eight voluntary healthy men > 18 years and weighing at least 60 kg. Men with a body mass index > 30 kg/m 2 , previous history of intolerance to the study drug or related compounds and additives, concomitant drug therapy of any kind except paracetamol in the 14 days prior to the study, existing or recent significant disease, history of any kind of drug allergy, previous or present alcoholism, drug abuse, psychological or other emotional problems, special diet or lifestyle, or clinically significant abnormal findings in physical examination, electrocardiographic (ECG) or laboratory screening were considered ineligible. Additionally, blood donation within 6 weeks prior to and during the study and participation in any other clinical study involving investigational or marketed drug products, and smoking within 1 month prior to study entry and during the study were prohibited. It was defined in the protocol that six participants must have undergone two treatment periods for study completion. Six of the eight participants were initially allocated into the study group, and two remained in reserve to replace participants in case of a common cold or other condition jeopardizing the reliability of the results after intranasal administration of dexmedetomidine or withdrawal of an individual for some other reason.
A two-period, cross-over design with balanced randomization was used. The participants were given 84 μg bolus doses of dexmedetomidine once intravenously and once intranasally in a randomized order. The washout period between the two administrations was at least 7 days. The study protocol specified that at least six participants had to undergo two evaluable treatment periods for study completion. Prior to the study, the participants had to refrain from the use of any drugs known to cause enzyme induction or inhibition for 30 days, any medications and some natural products (including grapefruit products) for at least 14 days, and alcohol and caffeine-containing products for at least 24 h. On the study days, the participants had to fast from midnight until 4 h after study drug administration. During this period, only water intake was allowed. A venous catheter was inserted into a large forearm vein for administration of dexmedetomidine and other drugs potentially needed to treat adverse events. An arterial catheter was inserted into the radial artery for blood sampling and blood pressure monitoring. ECG, invasive blood pressure, and peripheral arteriolar oxygen saturation (SpO 2 ) were monitored continuously. The participants were served standard meals 4 h and 8 h after dexmedetomidine administration.
Study treatments
A dose of 84 μg of dexmedetomidine (0.84 ml of dexmedetomidine hydrochloride 118 μg/ml, corresponding to dexmedetomidine base 100 μg/ml, Precedex®, Hospira, Lake Forest, IL, USA) was administered intravenously over 10 min at a constant rate using an infusion pump. Another dose of 84 μg of a more concentrated veterinary formulation (0.2 ml of dexmedetomidine hydrochloride 500 μg/ml, corresponding to dexmedetomidine base 420 μg/ml, Dexdomitor®, Orion Oyj, Espoo, Finland) was administered intranasally using a nasal spray application system (Spray Pump VP7/100S, 0.1 ml/dose, Valois Pharma, Le Vaudreuil, France) -one dose in each nostril.
Blood sampling
Arterial blood samples were collected immediately prior to administration of dexmedetomidine (baseline) and thereafter at 5, 10, 15, 20, 30, and 45 min and 1, 1.5, 2, and 3 h to determine concentrations of dexmedetomidine, adrenaline, and noradrenaline in plasma. Additional blood samples were collected at 4, 5, 6, 8, and 10 h after dexmedetomidine administration to determine dexmedetomidine. Ethylenediaminetetraacetate (EDTA) was used as the anticoagulant.
Dexmedetomidine and catecholamine analysis
Dexmedetomidine concentrations in plasma were determined with a fully validated [5] method based on reversephase high-performance liquid chromatography with tandem mass spectrometric detection (HPLC-MS/MS; Shimadzu Prominence HPLC connected to an AB Sciex API4000 mass spectrometer) based on a previously published method [6] . The mobile phase was 0.1% formic acid in a mixture of 1:1:1 (v/v/v) methanol/acetonitrile/water. The lower limit of quantitation was 0.02 ng/ml. The within-and between-run precision of the assay (coefficient of variation) was within 8% in the relevant concentration range. Concentrations of adrenaline and noradrenaline in plasma were measured using HPLC and coulometric electrochemical detection [7] .
Pharmacokinetic analysis
The peak drug concentrations in plasma (C max ) and the corresponding time points (t max ) were directly determined from the data. Areas under the dexmedetomidine plasma concentration-time curves were estimated using the trapezoidal rule with extrapolation to infinity (AUC 0À1 ). We used the linear trapezoidal rule when successive concentration values were increasing and the logarithmic trapezoidal rule when successive concentration values were decreasing after the peak concentration. For each participant, the terminal log-linear phase of the dexmedetomidine plasma concentration-time curve was visually identified, and the elimination rate constant (k e ) was determined by regression analysis. The elimination half-life (t 1/2 ) was then calculated from the following equation: t1 2 ¼ ln2=k e : After intravenous administration of dexmedetomidine, plasma clearance (CL) and steady-state volume of distribution (V ss ) of dexmedetomidine were calculated with noncompartmental methods based on statistical moment theory. The bioavailability of intranasally administered dexmedetomidine (F) was calculated as follows:
The pharmacokinetic data were analyzed with the WinNonlin pharmacokinetic program (version 4.1; Pharsight, Mountain View, CA, USA).
Pharmacodynamic measurements
Heart rate, systolic and diastolic blood pressure, and adrenaline and noradrenaline concentrations in plasma were measured to assess the sympatholytic effects of dexmedetomidine. The Maddox wing test was used to measure the effect of dexmedetomidine on the coordination of the extraocular muscles [8] , and the Bispectral Index (BIS) was used to monitor the level of sedation [9] . Subjective effects were recorded with 100-mm horizontal visual analog scales (VAS) with opposite qualities at each end (no effects of the drug/ very strong effects of the drug, excellent performance/poor performance, alert/drowsy) [10] . For adrenaline and noradrenaline concentrations and each pharmacodynamic variable, the area under the concentration-time curve (AUC) or response-time curve (AUEC) was determined using the trapezoidal rule in fractions of 0-0.5, 0-3, or 0-10 h, depending on the duration of recording of each variable.
Assessment of local tolerability
The tolerability of intranasally administered dexmedetomidine was assessed with VAS by the study participants and by visual inspection by the investigator immediately prior to administration (baseline) and thereafter at 1, 5, and 10 h. Subjective effects (no irritation/strong irritation, no obstruction/total obstruction, no numbness/total numbness, no rhinorrhea/ strong rhinorrhea) were recorded using VAS, as described above. In the visual inspection by the investigator, possible local mucosal irritation, inflammation, bleeding, and ulcerations were recorded. For each VAS value, the AUEC was determined for 10 h using the trapezoidal rule.
Statistical analysis
Results are expressed as medians (range). The Wilcoxon signed rank test was used, and differences were regarded as significant at P < 0.05. All data were analyzed using PASW Statistics 18.0 for Mac (SPSS Inc, Chicago, IL, USA). The primary outcome variables in this study were the observed dexmedetomidine concentrations in plasma and its calculated pharmacokinetic parameters. Secondary variables were heart rate, blood pressure, plasma adrenaline and noradrenaline concentrations, sedative effects, and possible local effects of intranasally administered dexmedetomidine.
Results
One participant informed in the morning of the second study day that he had caught a common cold, and he was replaced in that study session by a reserve participant. Once the participant with the flu had recovered, a third study session was arranged for him and the replacing participant. Therefore, there were seven participants in both treatment periods. Intranasal administration failed in one participant because of a handling error of the nasal application system. This participant was excluded from the analysis. Thus, seven individuals participated in the study but only six successfully completed the study and were included in the analyses.
Pharmacokinetics
The calculated pharmacokinetic parameters are shown in Table 1 and the median (range) plasma concentrations of dexmedetomidine are shown in Fig. 1 . The values of C max were 0.34 (0.23-0.70) and 3.48 (2.70-3.72) ng/ml after intranasal and intravenous administration, respectively. The median value for t max was 38 (15-60) min after intranasal administration. The corresponding values for t 1/2 were 114 (107-151) and 115 (99-145) min and for dexmedetomidine AUC 0À1 74.1 (45.7-114.4) and 123.6 (92.2-138.4) min·ng/ml. The number of participants having dexmedetomidine concentrations below the lower limit of quantitation was one at 8 h and five at 10 h following intravenous administration. Following intranasal administration, the corresponding numbers were two at 8 h and four at 10 h, respectively. Dexmedetomidine concentrations could be quantitated in all other samples drawn after the administration of dexmedetomidine. The median absolute bioavailability of intranasally administered dexmedetomidine was 65%, although the individual values had notable variation, ranging from 35% to 93%.
Pharmacodynamics
Heart rate and systolic and diastolic blood pressure were monitored for 10 h to assess the effects of dexmedetomidine (Fig. 2) . Based on the values for AUEC, heart rate was significantly (P = 0.046) lower during the initial 0-to 30-min period after intravenous than intranasal administration, but there was no statistically significant difference over the 0-to 10-h period. Systolic and diastolic blood pressure were similar regardless of the administration route and, no statistically significant differences between the treatments were noted.
There were no differences in plasma adrenaline concentrations based on AUC 0-30 min or AUC 0-3 h . Plasma noradrenaline AUC 0-30 min was significantly lower (P = 0.028) after intravenous than after intranasal administration, but the values for AUC 0-3 h did not differ (Fig. 3) .
Subjective effects (drug effect, performance, and drowsiness) and BIS results are shown in Fig. 4 . After intravenous administration, drug effects became apparent sooner compared with intranasal application: AUEC 0-30 min values of subjective effects, BIS, and the Maddox wing test were significantly (P < 0.05) different after intranasal and intravenous administration, but there were no differences in the AUEC 0-3 h values.
Local tolerability
There were no visible signs of local mucosal irritation, inflammation, bleeding, or ulceration of the nasal mucosa. In addition, no subjective adverse events were reported.
Discussion
Bioavailability of dexmedetomidine after oral and buccal administration has been described previously [11] , but the bioavailability after intranasal administration has remained undetermined. However, intranasal dexmedetomidine has been used successfully as premedication in children [3, 4] , and our study confirms that the bioavailability is sufficient to warrant further investigation of this route of administration. The large interindividual variation observed in our study participants attests to the need to develop and document an improved drug delivery system compared with the one used by us if intranasal application is to be clinically applicable. Results given as median and range C max peak plasma concentration t max time corresponding to C max ; AUC 0À1 area under dexmedetomidine plasma concentration-time curve, CL plasma clearance, Vss steady-state volume of distribution, F bioavailability.
The effects of intranasal dexmedetomidine were similar to those of intravenous dexmedetomidine judged by the AUEC, but -as expected -the onset of the effects was more rapid after intravenous administration. Onset of effects of intranasal dexmedetomidine was at 30-45 min after administration, which is in line with the observed C max of intranasal dexmedetomidine and previous experience in clinical pediatric patients [4] and adult volunteers [2] . If used for premedication before surgery or other invasive procedures, intranasal dexmedetomidine should optimally be administered 45-60 min before the start of the procedure.
Our study participants reported no numbness, irritation, bleeding, bad taste, or any other subjective effects after intranasally administered dexmedetomidine, and no local irritation of the nasal mucosa was observed by the investigators. These findings suggest that the intranasal route might be a safe method of administering dexmedetomidine. However, this aspect has to be confirmed in a larger number of study participants and also in actual patients. Nevertheless, the volume, formulation, and site of intranasal spray application may be of crucial importance when any drug is administered via this route. Indeed, we failed in the intranasal application in one participant, although we had practised the use of the application system. In the clinical situation, dosing with nasal spray administration may be even more difficult to accomplish than in an experimental setting, especially in children. Development of an optimized formulation and nasal delivery system is clearly required for this route to be clinically applicable. Nevertheless, it likely makes no great difference for absorption if part of the dexmedetomidine dose ends up in the pharynx and mouth, because dexmedetomidine is also readily absorbed from the oral mucosa [11] . However, if the applied volume is too large, part of the administered drug will be swallowed, causing impaired bioavailability because of first-pass metabolism, and diminished efficacy. According to the literature [4] , intranasally administered dexmedetomidine has mainly been used as premedication in pediatric patients. The intranasal route is an efficacious and rather comfortable way to administer dexmedetomidine, particularly in children afraid of needles, and this route could be favored over intravenous or intramuscular administration. The intranasal route could also be a convenient and safe means of providing dexmedetomidine sedation and analgesia for terminally ill patients.
This study has several limitations. It involved a rather small number of healthy volunteers. However, it was not intended to be a formal bioequivalence study, but its aim was to characterize the pharmacokinetics and pharmacodynamics of intranasally administered dexmedetomidine compared with its intravenous administration. The absolute dose of delivered intranasally remains uncertain, even though we had practiced administration, and the commercial application system we used was specifically designed for this purpose [the manufacturer of system guarantees that the volume administered is 0.1 ml±10%, which was verified by us with weighing experiments performed in the laboratory (results not shown)]. It is possible that part of the intranasal drug solution ran from the nasal cavity to the pharynx and was swallowed, even though the volume of the dexmedetomidine solution was small (0.1 ml / nostril) and the administration was synchronized with the inspirium to maximize the spread of the aerosol within the nasal cavity. This inaccuracy in dosing probably caused part of the large variation in nasal bioavailability between participants. Even if the range of individual nasal bioavailability estimates was broad (35-93%), five of the six individual estimates of bioavailability exceeded 50%. Such variability in bioavailability is not unusual when unmodified intravenous preparations are used for intranasal drug administration [12] . An optimized delivery system for the intranasal route would most likely improve the bioavailability and reduce its interindividual variability.
In conclusion, the bioavailability of intranasally administered dexmedetomidine is good, its administration is efficacious, and it seems to be well tolerated, making it suitable for clinical situations requiring light sedation. According to our study, dexmedetomidine should be administered intranasally 45-60 min prior to the desired moment of maximal effect. 
